Projects per year
Organisation profile
Organisation profile
Our research focuses on developing gene therapy approaches for highly prevalent diseases, such as diabetes mellitus and obesity, and rare metabolic/neurodegenerative diseases. Obesity and type 2 diabetes, strongly associated with deficits in cognitive function, are a major health problem because of their alarming growing prevalence worldwide. Novel adeno-associated viral (AAV) vector-mediated gene therapy strategies are used to target these pathophysiological processes. We are also developing gene therapies for Mucopolysaccharidosis, a group of devastating lysosomal storage diseases that currently lack effective treatments. We aim at developing gene therapies that are minimally invasive, safe and could guarantee maximal efficacy in the most affected organs. The know-how derived from these studies is also used to assess the effectiveness of AAV-based gene therapeutics products to counteract other neurodegenerative diseases and rare diseases affecting the skeletal system in mouse models.
Directed by:
Fàtima Bosch Tubert
Research lines
- Research lines:
- GENE THERAPY APPROACHES FOR DIABETES MELLITUS, OBESITY AND ASSOCIATED COMORBIDITIES
- GENE THERAPY APPROACHES FOR RARE METABOLIC AND NEUROGENERATIVE DISEASES
- GENE THERAPY FOR HIGHLY PREVALENT NEURODEGENERATIVE DISEASES
Fingerprint
Collaborations and top research areas from the last five years
Profiles
-
Ivet Elias Puigdomenech
- Centre for Animal Biotechnology and gene Therapy (CBATEG)
- Laboratori d'Enginyeria Genètica Animal i Teràpia Gènica
Person: Accredited TSR, Affiliation to research
-
Sylvie Laure Franckhauser Vogel
- Centre for Animal Biotechnology and gene Therapy (CBATEG)
- Laboratori d'Enginyeria Genètica Animal i Teràpia Gènica
Person: Superior technician research support , Accredited TSR, Affiliation to research
-
ERDERA: EUROPEAN RARE DISEASES RESEARCH ALLIANCE
Marcó Costa, S. (Investigator), Godia Casablancas, F. (Investigator), García Martínez, M. (Technician), Cervera Gracia, L. (Investigator), Franckhauser Vogel, S. L. (Investigator) & Bosch Tubert, M. F. (Principal Investigator)
1/09/24 → 31/08/31
Project: International research project
-
INFRAPLUS: Enhancing and Evolving INFRAFRONTIER Disease Modelling Capacity to Enable Breakthrough Research
Bosch Tubert, M. F. (Principal Investigator), Ruberte Paris, J. (Co-Investigador/a Principal), Carretero Romay, A. M. (Investigator), Elias Puigdomenech, I. (Investigator), Franckhauser Vogel, S. L. (Investigator), García Martínez, M. (Investigator), Jimenez, V. (Investigator), León Madrenas, X. (Investigator), Nacher Garcia, V. (Investigator), Navarro Beltran, M. (Investigator) & Marcó Costa, S. (Investigator)
1/06/24 → 31/05/27
Project: International research project
-
CIBERDEM: CIBERDEM_ Disfunción, destrucción, regeneración del islote Autoinmunidad
Bosch Tubert, M. F. (Principal Investigator), Barrero Victorio, J. (Investigator), Carretero Romay, A. M. (Investigator), Casaña Lorente, E. (Investigator), Casellas Comallonga, A. (Investigator), Elias Puigdomenech, I. (Investigator), Ferré Masferrer, M. D. T. (Investigator), Franckhauser Vogel, S. L. (Investigator), García Martínez, M. (Investigator), Jambrina Pallares, C. (Investigator), Jimenez, V. (Investigator), León Madrenas, X. (Investigator), Melgarejo Bermudez, V. (Investigator), Molas Laplana, M. (Investigator), Morro Larrubia, M. (Investigator), Moya Martínez, M. (Investigator), Muñoz Forero, S. A. (Investigator), Nacher Garcia, V. (Investigator), Navarro Beltran, M. (Investigator), Otaegui Goya, P. J. (Investigator), Pujol, A. (Investigator), Ribera Sanchez, A. (Investigator), Roca Lecha, C. (Investigator), Ruberte Paris, J. (Investigator), Vila Prats, L. (Investigator), Zaguirre Sánchez, M. (Investigator), Marcó Costa, S. (Investigator), Jaen Sitges, M. L. (Investigator), Sacristan Fraile, V. (Investigator) & Jaramillo Garces, S. P. (Collaborator)
1/01/09 → 31/12/30
Project: Research Projects and Other Grants
-
Beating the empty pelvis syndrome: the PelvEx Collaborative core outcome set study protocol
PelvEx Collaborative, 5 Feb 2024, In: BMJ Open. 14, 2, p. e076538 e076538.Research output: Contribution to journal › Article › Research › peer-review
Open Access -
REVERSION OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS BY SKELETAL MUSCLE-DIRECTED FGF21 GENE THERAPY
Bosch Tubert, M. F., Jimenez, V., Sacristan Fraile, V., Jambrina Pallares, C., Jaen Sitges, M. L., Casaña Lorente, E., Muñoz Forero, S. A., Marcó, S., Molas, M., García Martínez, M., Grass, I., León, X., Elias Puigdomenech, I., Ribera, A., Elias, G., Sanchez Clares, V., Vilà, L., Casellas, A., Ferré, T. & Rodó, J. & 10 others, , 4 Dec 2024, In: Molecular Therapy. 32, 12, p. 4285-4302 18 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access4 Citations (Scopus) -
The empty pelvis syndrome: a core data set from the PelvEx collaborative
PelvEx Collaborative, 1 Mar 2024, In: British Journal of Surgery. 111, 3, 14 p., znae042.Research output: Contribution to journal › Article › Research › peer-review
Open Access8 Citations (Scopus)
Student theses
-
Gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome)
Motas Mallol, S. (Author), Bosch Tubert, M. F. (Director) & Haurigot Mendoça, V. (Director), 11 Jul 2016Student thesis: Doctoral thesis